August 6, 2020

Grassley Statement on Trump Executive Order on Domestic Drug Manufacturing

Washington – Senate Finance Committee Chairman Chuck Grassley
(R-Iowa) today released the following statement regarding President Donald
Trump’s executive
order
encouraging domestic manufacturing of drugs and other medical goods
critical to public health.

 

“The
coronavirus pandemic exposed many weaknesses in our medical supply chain.
There’s no question that our reliance on certain countries for personal
protective equipment, medicine and other goods make containing this deadly
disease much tougher. It’s now clear that supply chain diversification and
increased domestic manufacturing of medical products is critical to preserving
our country’s ability to respond to major public health crises,” Grassley
said.
“Unfortunately, the coronavirus pandemic caused health care workers,
patients, businesses and all Americans to learn this the hard way. This
shouldn’t be a mistake we make twice. These are structural problems exacerbated
by years of inaction from previous administrations of both parties. President
Trump is right to do all he can to encourage domestic manufacturing. It will be
up to Congress to finish the job.”

 

Grassley
has long been an advocate for increased access to affordable prescription drugs
and this year authored

the bipartisan Prescription Drug Pricing Reduction Act of 2020.

 

Last
week, Grassley led a two-part oversight hearing on protecting the reliability
of the U.S. medical supply chain during the COVID-19 pandemic. Those hearings
can be viewed here

and here
and Grassley’s statements can be found here
and here.

 

In
June, Grassley led a hearing

on the Food and Drug Administration’s (FDA) foreign drug manufacturing
inspection process. His statement from that hearing can be found here. 

Print 
Email 
Share 
Share